Published in J Clin Invest on October 08, 2014
Recombinant Laminins Drive the Differentiation and Self-Organization of hESC-Derived Hepatocytes. Stem Cell Reports (2015) 0.95
In vivo models of hepatitis B and C virus infection. FEBS Lett (2016) 0.85
Amelioration of Hyperbilirubinemia in Gunn Rats after Transplantation of Human Induced Pluripotent Stem Cell-Derived Hepatocytes. Stem Cell Reports (2015) 0.84
Determinants of hepatitis B and delta virus host tropism. Curr Opin Virol (2015) 0.82
Assessing the therapeutic potential of lab-made hepatocytes. Hepatology (2016) 0.80
Characterisation of liver pathogenesis, human immune responses and drug testing in a humanised mouse model of HCV infection. Gut (2015) 0.78
Human stem cell-derived hepatocytes as a model for hepatitis B virus infection, spreading and virus-host interactions. J Hepatol (2016) 0.78
Hepatic differentiation of human pluripotent stem cells in miniaturized format suitable for high-throughput screen. Stem Cell Res (2016) 0.78
Experimental models of hepatitis B and C - new insights and progress. Nat Rev Gastroenterol Hepatol (2016) 0.76
Hepatocyte-like cells derived from induced pluripotent stem cells. Hepatol Int (2016) 0.76
Transplantation of hESC-derived hepatocytes protects mice from liver injury. Stem Cell Res Ther (2015) 0.76
Rhesus iPSC Safe Harbor Gene-Editing Platform for Stable Expression of Transgenes in Differentiated Cells of All Germ Layers. Mol Ther (2017) 0.75
Modeling Viral Infectious Diseases and Development of Antiviral Therapies Using Human Induced Pluripotent Stem Cell-Derived Systems. Viruses (2015) 0.75
The Role of Type III Interferons in Hepatitis C Virus Infection and Therapy. J Immunol Res (2017) 0.75
Cell therapy from bench to bedside: Hepatocytes from fibroblasts - the truth and myth of transdifferentiation. World J Gastroenterol (2015) 0.75
Generation of Human Liver Chimeric Mice with Hepatocytes from Familial Hypercholesterolemia Induced Pluripotent Stem Cells. Stem Cell Reports (2017) 0.75
Recapitulation of treatment response patterns in a novel humanized mouse model for chronic hepatitis B virus infection. Virology (2016) 0.75
Statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents. F1000Res (2016) 0.75
Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell (2007) 101.42
Induced pluripotent stem cell lines derived from human somatic cells. Science (2007) 71.50
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 21.56
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci U S A (2008) 13.09
Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol (2005) 9.11
Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology (2010) 6.40
Hepatitis C virus replication in mice with chimeric human livers. Nat Med (2001) 5.87
Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci U S A (2005) 5.64
Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature (2013) 5.43
Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol (2002) 4.55
Current and future therapies for hepatitis C virus infection. N Engl J Med (2013) 4.25
Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci U S A (2007) 4.05
Differentiation and transplantation of human embryonic stem cell-derived hepatocytes. Gastroenterology (2008) 3.99
Real-time detection system for quantification of hepatitis C virus genome. Gastroenterology (1999) 3.83
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A (2006) 3.69
Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J Virol (2007) 3.57
Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Nat Biotechnol (2010) 3.44
A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc Natl Acad Sci U S A (2009) 3.37
Generation of functional human hepatic endoderm from human induced pluripotent stem cells. Hepatology (2010) 3.36
Directed differentiation of human embryonic stem cells into functional hepatic cells. Hepatology (2007) 3.29
Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J Virol (2007) 3.18
Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest (2010) 3.10
Visualizing hepatitis C virus infections in human liver by two-photon microscopy. Gastroenterology (2009) 3.07
Highly efficient differentiation of hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signaling. Proc Natl Acad Sci U S A (2008) 2.99
Excision of reprogramming transgenes improves the differentiation potential of iPS cells generated with a single excisable vector. Stem Cells (2010) 2.62
Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures. Proc Natl Acad Sci U S A (2010) 2.44
Efficient differentiation of functional hepatocytes from human embryonic stem cells. Stem Cells (2008) 2.29
Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology (2010) 2.28
Mouse liver repopulation with hepatocytes generated from human fibroblasts. Nature (2014) 2.23
Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proc Natl Acad Sci U S A (2012) 2.20
Direct reprogramming of human fibroblasts to functional and expandable hepatocytes. Cell Stem Cell (2014) 2.15
The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am J Gastroenterol (2006) 2.13
HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology (2012) 2.08
An in vitro model of hepatitis C virion production. Proc Natl Acad Sci U S A (2005) 1.86
Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes. Gastroenterology (2010) 1.85
Human hepatocytes with drug metabolic function induced from fibroblasts by lineage reprogramming. Cell Stem Cell (2014) 1.83
Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice. J Hepatol (2010) 1.70
Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol (2010) 1.67
In vivo liver regeneration potential of human induced pluripotent stem cells from diverse origins. Sci Transl Med (2011) 1.66
HNF4A is essential for specification of hepatic progenitors from human pluripotent stem cells. Development (2011) 1.50
Emergence of a distinct pattern of viral mutations in chimpanzees infected with a homogeneous inoculum of hepatitis C virus. Gastroenterology (2001) 1.45
Hepatocyte transplantation into diseased mouse liver. Kinetics of parenchymal repopulation and identification of the proliferative capacity of tetraploid and octaploid hepatocytes. Am J Pathol (2000) 1.39
Cutting the gordian knot-development and biological relevance of hepatitis C virus cell culture systems. Adv Virus Res (2008) 1.33
Productive hepatitis C virus infection of stem cell-derived hepatocytes reveals a critical transition to viral permissiveness during differentiation. PLoS Pathog (2012) 1.29
Production of infectious hepatitis C virus of various genotypes in cell cultures. J Virol (2007) 1.27
Directed differentiation of pluripotent stem cells: from developmental biology to therapeutic applications. Cold Spring Harb Symp Quant Biol (2009) 1.25
New potential for human embryonic stem cells. Science (1998) 1.21
3D spheroid culture of hESC/hiPSC-derived hepatocyte-like cells for drug toxicity testing. Biomaterials (2012) 1.19
Repopulation efficiencies of adult hepatocytes, fetal liver progenitor cells, and embryonic stem cell-derived hepatic cells in albumin-promoter-enhancer urokinase-type plasminogen activator mice. Am J Pathol (2009) 1.18
Direct and indirect contribution of human embryonic stem cell-derived hepatocyte-like cells to liver repair in mice. Gastroenterology (2011) 1.17
Integrative functional genomics of hepatitis C virus infection identifies host dependencies in complete viral replication cycle. PLoS Pathog (2014) 1.11
Reprogramming induced pluripotent stem cells in the absence of c-Myc for differentiation into hepatocyte-like cells. Biomaterials (2011) 1.04
Differentiation and transplantation of human induced pluripotent stem cell-derived hepatocyte-like cells. Stem Cell Rev (2013) 0.98
The promotion of hepatic maturation of human pluripotent stem cells in 3D co-culture using type I collagen and Swiss 3T3 cell sheets. Biomaterials (2012) 0.95
Spheroid culture for enhanced differentiation of human embryonic stem cells to hepatocyte-like cells. Stem Cells Dev (2013) 0.93
Chimeric mouse model for the infection of hepatitis B and C viruses. PLoS One (2013) 0.89
Hepatic differentiation and maturation of human embryonic stem cells cultured in a perfused three-dimensional bioreactor. Stem Cells Dev (2012) 0.88
Application of three-dimensional culture conditions to human embryonic stem cell-derived definitive endoderm cells enhances hepatocyte differentiation and functionality. Tissue Eng Part A (2012) 0.86
Enhanced functions of human embryonic stem cell-derived hepatocyte-like cells on three-dimensional nanofibrillar surfaces. Stem Cell Rev (2010) 0.85
Hepatic differentiation from human embryonic stem cells using stromal cells. J Surg Res (2011) 0.81
In vitro veritas? The challenges of studying hepatitis C virus infectivity in a test tube. J Hepatol (2006) 0.79
Engraftment potential of spheroid-forming hepatic endoderm derived from human embryonic stem cells. Stem Cells Dev (2013) 0.79
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 21.56
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31
Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science (2014) 5.47
SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab (2007) 4.75
Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D. JAMA (2008) 4.74
Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol (2002) 4.56
Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A (2004) 4.17
Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet (2004) 3.97
Cost-related medication nonadherence among elderly and disabled medicare beneficiaries: a national survey 1 year before the medicare drug benefit. Arch Intern Med (2006) 3.96
Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology (2006) 3.95
Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest (2006) 3.95
Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology (2007) 3.87
Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet (2013) 3.87
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A (2006) 3.69
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology (2004) 3.61
Management of hepatitis B: summary of a clinical research workshop. Hepatology (2007) 3.40
A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc Natl Acad Sci U S A (2009) 3.37
Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med (2008) 3.33
Effect of pay for performance on the management and outcomes of hypertension in the United Kingdom: interrupted time series study. BMJ (2011) 3.29
Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1. Nat Med (2010) 3.27
Hepatitis C virus infection activates an innate pathway involving IKK-α in lipogenesis and viral assembly. Nat Med (2013) 3.24
Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet (2011) 3.18
Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J Clin Invest (2007) 2.80
Progression of fibrosis in chronic hepatitis C. Gastroenterology (2003) 2.77
The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology (2010) 2.75
Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology (2002) 2.64
Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology (2004) 2.64
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology (2011) 2.63
Temporal competition between differentiation programs determines cell fate choice. Mol Syst Biol (2011) 2.61
A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res (2010) 2.59
Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest (2007) 2.53
Effects of a law against early postpartum discharge on newborn follow-up, adverse events, and HMO expenditures. N Engl J Med (2002) 2.41
Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology (2009) 2.41
Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology (2012) 2.40
Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology (2011) 2.39
Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology (2002) 2.38
Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees. Hepatology (2004) 2.37
Effect of quality improvement on racial disparities in diabetes care. Arch Intern Med (2006) 2.36
Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells. J Virol (2005) 2.33
Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology (2011) 2.33
Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol (2002) 2.31
Trends and geographic variation of opiate medication use in state Medicaid fee-for-service programs, 1996 to 2002. Med Care (2006) 2.28
Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology (2010) 2.28
Effect of New York State regulatory action on benzodiazepine prescribing and hip fracture rates. Ann Intern Med (2007) 2.27
Access to care and medicines, burden of health care expenditures, and risk protection: results from the World Health Survey. Health Policy (2010) 2.25
Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management. Diabetes Care (2007) 2.22
Failure of automated telephone outreach with speech recognition to improve colorectal cancer screening: a randomized controlled trial. Arch Intern Med (2010) 2.21
Cost-related medication nonadherence in older patients with rheumatoid arthritis. J Rheumatol (2013) 2.17
Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology (2013) 2.17
GTF2IRD1 in craniofacial development of humans and mice. Science (2005) 2.15
DLC-1:a Rho GTPase-activating protein and tumour suppressor. J Cell Mol Med (2007) 2.09
Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol Ther (2006) 2.08
HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology (2012) 2.08
Thioacetamide-induced hepatic fibrosis in transforming growth factor beta-1 transgenic mice. Eur J Gastroenterol Hepatol (2004) 2.06
Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol (2010) 2.05
Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology (2008) 2.04
Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology (2010) 2.03
A critical review of methods to evaluate the impact of FDA regulatory actions. Pharmacoepidemiol Drug Saf (2013) 2.00
Race differences in long-term diabetes management in an HMO. Diabetes Care (2005) 1.98
Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol (2006) 1.98
A WAVE-1 and WRP signaling complex regulates spine density, synaptic plasticity, and memory. J Neurosci (2007) 1.97
Loss of AKAP150 perturbs distinct neuronal processes in mice. Proc Natl Acad Sci U S A (2008) 1.96
Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J Virol (2003) 1.93
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology (2007) 1.92
Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology (2003) 1.91
DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene (2004) 1.90
The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J Virol (2003) 1.90
The SH3 binding motif of HCV [corrected] NS5A protein interacts with Bin1 and is important for apoptosis and infectivity. Gastroenterology (2006) 1.89
Label-retaining liver cancer cells are relatively resistant to sorafenib. Gut (2013) 1.89
Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology (2003) 1.87
Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology (2008) 1.87
Benzodiazepine use and hip fractures in the elderly: who is at greatest risk? Arch Intern Med (2004) 1.86
An in vitro model of hepatitis C virion production. Proc Natl Acad Sci U S A (2005) 1.86
Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes. Gastroenterology (2010) 1.85
Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res (2010) 1.82
Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology (2002) 1.81
Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med (2011) 1.81
Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. FEBS J (2014) 1.79
New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1. J Virol (2005) 1.78
Use of interrupted time series analysis in evaluating health care quality improvements. Acad Pediatr (2013) 1.76
Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. Gastroenterology (2013) 1.76
DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity. Oncogene (2003) 1.76
Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling. Hepatology (2014) 1.74
Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness. Med Care (2010) 1.74
Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med (2011) 1.74
Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther (2004) 1.72
Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology (2007) 1.72
Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology (2004) 1.71
Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology (2007) 1.70
Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology (2010) 1.70
Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology (2011) 1.68
Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding. Virology (2002) 1.67
The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia. Cancer Res (2004) 1.67
Interaction of hepatitis C virus-like particles and cells: a model system for studying viral binding and entry. J Virol (2002) 1.66
Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci U S A (2007) 1.66
Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J Clin Invest (2006) 1.66
Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells. Oncogene (2004) 1.65
Evidence for a functional RNA element in the hepatitis C virus core gene. Proc Natl Acad Sci U S A (2007) 1.64